Jan 27 (Reuters) – The U.S. Centers for Medicare & Medicaid Services on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028 including Pfizer arthritis treatment Xeljanz, Eli Lilly’s diabetes drug Trulicity and AbbVie’s cosmetic treatment Botox.
It is the third round of drugs subject to the annual price negotiations established under President Joe Biden’s signature Inflation Reduction Act (IRA) of 2022.
For the first time, the list includes the first products reimbursed under Medicare Part B.
The U.S. Medicare health plan said last year that newly negotiated prices for the 15 drugs it negotiated prices for 2027 will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs.
(Reporting by Michael Erman in New Jersey and Siddhi Mahatole in Bengaluru; Editing by Alan Barona and Franklin Paul)
Comments